Form SC 13G June 22, 2018
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No)*
SORRENTO THERAPEUTICS, INC.
(Name of Issuer)
Common Stock, \$0.0001 par value
(Title of Class of Securities)
83587F202
(CUSIP Number)

Sorrento Therapeutics, Inc.

December 21, 2017
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
oRule 13d-1(b)
þRule 13d-1(c)

oRule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

^{*} The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

CUSIP No. 83587F202

Name of Reporting Person

Hongguo International
Holdings Limited
Check the Appropriate Box if
a Member of a Group (See
Instructions)

2 (a) "

4

(b) "
SEC Use Only

3 Citizenship or Place of Organization

British Virgin Islands

Sole Voting Power

5

 $4,407,713^{(1)}$

Shared Voting Power

number of shares 0 beneficially owned by

each Sole Dispositive Power

reporting person with 7

 $4,407,713^{(1)}$

0

Aggregate Amount Beneficially Owned by Each Reporting Person

9

 $4,407,713^{(1)}$

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

10

Percent of Class Represented by Amount in Row (9)

11

 $5.0\%^{(2)}$

Type of Reporting Person (See Instructions)

12

 \mathbf{CO}

⁽¹⁾ Comprised solely of shares of the Issuer's common stock <u>("Common Stock")</u> issuable upon conversion of a convertible promissory note issued by the Issuer to Hongguo International Holdings Limited (the <u>"Reporting Person")</u> on December 21, 2017 (the <u>"Note")</u>.

Edgar Filing: Sorrento Therapeutics, Inc. - Form SC 13G

⁽²⁾ Percentage based on 82,903,567 shares of Common Stock outstanding as of December 21, 2017, based on information provided by the Issuer to the Reporting Person plus, 4,407,713 shares of Common Stock issuable upon conversion of the Note.

Page 3 of 6 Pages
Item 1.
(a) Name of Issuer
Sorrento Therapeutics, Inc.
(b) Address of Issuer's Principal Executive Offices
4955 Directors Place
San Diego, CA 92121
Item 2.
(a) Name of Person Filing
Hongguo International Holdings Limited (the "Reporting Person")
(b) Address of Principal Business office or, if None, Residence
Room 2904, 29th Floor, East Finance Centre
16 Harcourt Road, Admiralty, Hong Kong

(c)	Citizenship	
Britisl	Virgin Islands	
(d)	Title of Class of Securities	
Comn	on Stock, \$0.0001 par value (<u>"Common Stock"</u>)	
(e)	CUSIP Number	
83587	202	
Item :	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person a:	filing is
	" Broker or dealer registered under section 15 of the Act (15 U.S.C. 780);	
	(b) "Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);	
	(c) "Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80)	a-8):
(d)	(e) "An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);	,,
	f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);	
	"A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);	
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 18	13);
	church plan that is excluded from the definition of an investment company under section 3(c)(14) of the street Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);	ne

Edgar Filing: Sorrento Therapeutics, Inc. - Form SC 13G

Group, in accordance with $\$ 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with $\$ 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

	Item 4.	Ownership.
(a)	Amount beneficially owned:	
4,407,7	713*	
(b)	Percent of class:	
5.0%*	*	
(c)	Number of shares as to which the person has:	
(i) Sole	power to vote or to direct the vote:	
4,407,	713*	
(ii)Sha	ared power to vote or to direct the vote:	
0		
(iii) So	le power to dispose or to direct the disposition of:	
4,407,7	713*	
(iv)Sh	ared power to dispose or to direct the disposition of:	

0

*Comprised of 4,407,713 shares of Common Stock issuable upon conversion of a convertible promissory note issued by the Issuer to the Reporting Person on December 21, 2017 (the "Note").

Percentage based on 82,903,567 shares of Common Stock as of December 21, 2017, based on information provided ** by the Issuer to the Reporting Person, plus 4,407,713 shares of Common Stock issuable upon conversion of the Note.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following "

Item 6.	Ownershi	p of More than	Five Percent	on Behalf of	Another Person

Yixi Chen, the Director of the Reporting Person, may be deemed to have voting and dispositive power over the shares held by the Reporting Person.

Item Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on Bythe Parent Holding Company or Control Person.

N/A

Item 8. Identification and Classification of Members of the Group.

N/A

Item 9. Notice of Dissolution of Group.

N/A

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Edgar Filing: Sorrento Therapeutics, Inc. - Form SC 13G

Page	6	of	6	P	ages
------	---	----	---	---	------

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: June 22, 2018

Hongguo International Holdings Limited

By: /s/ Yixi Chen Name: Yixi Chen

Title: Director